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Infections caused by multidrug-resistant Acinetobacter baumannii are a major public health problem, and polymyxins are often
the last line of therapy for recalcitrant infections by such isolates. The pharmacokinetics of the two clinically used polymyxins,
polymyxin B and colistin, differ considerably, since colistin is administered as an inactive prodrug that undergoes slow conver-
sion to colistin. However, the impact of these substantial pharmacokinetic differences on bacterial killing and resistance emer-
gence is poorly understood.We assessed clinically relevant polymyxin B and colistin dosage regimens against one reference and
three clinical A. baumannii strains in a dynamic one-compartment in vitromodel. A new mechanism-based pharmacodynamic
model was developed to describe and predict the drug concentrations and viable counts of the total and resistant populations.
Rapid attainment of target concentrations was shown to be critical for polymyxin-induced bacterial killing. All polymyxin B reg-
imens achieved peak concentrations of at least 1 mg/liter within 1 h and caused >4 log10 killing at 1 h. In contrast, the slow rise
of colistin concentrations to 3 mg/liter over 48 h resulted in markedly reduced bacterial killing. A significant (4 to 6 log10 CFU/
ml) amplification of resistant bacterial populations was common to all dosage regimens. The developedmechanism-based model
explained the observed bacterial killing, regrowth, and resistance. The model also implicated adaptive polymyxin resistance as a
key driver of bacterial regrowth and predicted the amplification of preexisting, highly polymyxin-resistant bacterial populations
following polymyxin treatment. Antibiotic combination therapies seem the most promising option for minimizing the emer-
gence of polymyxin resistance.
The rise of multidrug-resistant (MDR) Gram-negative patho-gens, such as Acinetobacter baumannii, presents a global threat
to public health (1, 2). The number of antibiotics that remain
effective for the treatment of infections caused by these pathogens
continues to dwindle at an alarming rate, with few novel alterna-
tives in late-phase clinical development (3). This has driven a re-
surgence in the use of polymyxins to treat recalcitrant infections
that are resistant to most or all other currently available antibiotics
(4). The two clinically used polymyxins, colistin and polymyxin B,
differ substantially in clinical pharmacokinetics (PK) due to dif-
ferences in administered form. Although colistin and polymyxin B
have long been regarded as equivalent, clinical studies in critically
ill patients have revealed considerable differences in their PK (5–
12). Given the importance of polymyxins as last-line therapy, de-
veloping innovative dosage regimens for polymyxins will be crit-
ical to maintaining their efficacy against MDR pathogens.
Clinically, polymyxin B is administered in its active form
whereas colistin (polymyxin E) is administered as its inactive pro-
drug colistin methanesulfonate (CMS), which subsequently un-
dergoes slow conversion to colistin in patients (13). CMS is elim-
inated rapidly via the renal route in parallel with its gradual
conversion to colistin, and consequently a large proportion of
CMS is eliminated as CMS prior to conversion (14). Even when
CMS loading doses are used, the low rate of conversion from CMS
to colistin leads to delayed attainment of effective colistin concen-
trations (8). Conversely, administration of polymyxin B in its ac-
tive form allows target concentrations to be rapidly attained.
A clear association between the timely initiation of appropriate
antimicrobial therapy and patient survival has been established
for conditions such as ventilator-associated pneumonia and septic
shock (15–17). In light of this relationship, the differences in the
concentration-versus-time profiles of polymyxin B and colistin
may have a substantial impact on bacterial killing and clinical
outcomes. The differences in bacterial killing and the emergence
of resistance for polymyxin B and colistin during the initial stages
of polymyxin therapy with clinically relevant dosage regimens
have not been investigated.
The first aim of this study was to investigate, in A. baumannii,
the effect of polymyxin concentration-versus-time profiles from
standard and innovative (e.g., front-loading or augmented load-
ing dose) dosage regimens on bacterial killing and emergence of
resistance during the initial stages of polymyxin therapy. The sec-
ond aim was to quantitatively characterize and predict the impact
of polymyxin dosage regimens on antimicrobial activity and the
emergence of resistance by developing a novel, mechanism-based
mathematical model. To address these aims, experimental data
from a dynamic one-compartment in vitro infection model (IVM)
were integrated with pharmacokinetic/pharmacodynamic (PK/
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PD) modeling, enabling the interrogation and prediction of bac-
terial killing and regrowth for clinically relevant polymyxin dosage
regimens.
MATERIALS AND METHODS
Bacterial strains and isolates. One reference strain and three previously
reported (18–20) clinical isolates were examined in this study. These were
A. baumannii ATCC 19606 (MIC, 0.5 mg/liter), FADDI-AB008 (MIC, 0.5
mg/liter; described in reference 19 as isolate 8), FADDI-AB030 (MIC, 0.5
mg/liter; described in reference 20 as strain 248-01-C.248), and AB307-
0294 (MIC, 1 mg/liter). The polymyxin B and colistin MIC values were
identical for each of the strains. A. baumannii ATCC 19606 and FADDI-
AB008 have previously been identified as being heteroresistant (19), con-
sisting of predominantly polymyxin-susceptible bacteria but with a small
subpopulation of polymyxin-resistant bacteria (21). Population analysis
profiles (PAPs) for A. baumannii strain AB307-0294 showed evidence of
heteroresistance, while there was no evidence for heteroresistance in suscep-
tible strain FADDI-AB030. In A. baumannii ATCC 19606, polymyxin resis-
tance can occur via the modification of lipid A with phosphoethanolamine
(22) or the loss of lipopolysaccharide (LPS) from the outer membrane (23). In
the case of FADDI-AB008, only one mechanism of polymyxin resistance has
been reported, namely, the loss of LPS from the outer membrane (23).
Comparison of clinically relevant colistin and polymyxin B dosage
regimens. An IVM was used to simulate clinically relevant pharmacoki-
netic profiles for polymyxin B and colistin. The experimental setup for the
IVM did not employ a filter and was identical to that used in previously
published studies (24), except where described below. For each dosage
regimen and bacterial strain, an elimination half-life (t1/2) of 11.6 h and an
average steady-state concentration (Css,avg) of 3 mg/liter were simulated in
the IVM, guided by the results of previously published population PK
studies in critically ill patients (5, 8, 9, 25). Specifically, the elimination
half-life was chosen to be within the range of values reported (9 to 13 h) for
colistin formed from CMS and polymyxin B. Colistin and polymyxin B
are approximately 50% bound in plasma of critically ill patients (9, 26,
27). TheCss,avg of 3 mg/liter chosen for the studies in the IVM was selected
to represent the upper region of clinically achievable unbound concentra-
tions of each of the polymyxins. For colistin, an unbound Css,avg of 3
mg/liter represents the accumulation of colistin observed by Garonzik et
al. (5) for a patient with moderate renal impairment (creatinine clearance,
50 ml/min/1.73 m2) receiving a daily maintenance CMS dose of300
to 360 mg colistin base activity (CBA). A loading dose to more rapidly
attain a concentration of 3 mg/liter was not included because 300 to 360
mg CBA is in the vicinity of the upper limit of the recommended loading
dose (28). For polymyxin B, an unbound Css,avg of 3 mg/liter falls within
the 90th percentile for a patient receiving a maintenance dose of 3 mg/kg
per day reported by Sandri et al. (9).
The dosage regimens examined in the IVM (Fig. 1) were as follows: the
gradual accumulation of colistin with a half-life of 11.6 h, adapted from
previously reported (8) concentration-time profiles predicted for the ini-
tiation of therapy with CMS with no loading doses (regimen R1); poly-
FIG 1 Concentration-time profiles for colistin base (A) and polymyxin B base (B to D) of simulated (t1/2  11.6 h, Css,avg  3 mg/liter) clinically relevant
polymyxin dosage regimens. (A) Gradual rise of colistin (as seen in patients following CMS administration); (B) polymyxin B, 1-h infusion every 12 hours with
no loading dose; (C) polymyxin B, 1-h infusion every 12 hours with a conventional loading dose; (D) polymyxin B, 1-h infusion every 12 hours with an
augmented loading dose.
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myxin B, 1-h infusion every 12 h with no loading dose (R2); regimen R2
with a loading dose to rapidly achieve the steady-state concentration (R3);
and regimen R2 initiated with an augmented loading dose to achieve an
initial peak concentration of 6 mg/liter polymyxin B base with a subse-
quent decline to a Css,avg of 3 mg/liter (R4).
The volume and temperature of the central reservoir were 80 ml and
37°C, respectively, and cation-adjusted Mueller-Hinton broth was circu-
lated at a rate of 4.8 ml/h to achieve an elimination half-life of 11.6 h.
Viable counting was performed on drug-free and drug-containing (6.6
mg/liter polymyxin B base) plates at 0, 0.5, 1, 2, 4, 8, 11, 13, 23, 25, 26, 28,
47, 49, 50, 52, 71, 73, 74, 76, and 96 h. The PAPs were performed at 0, 23,
47, 71, and 96 h on polymyxin B-containing plates (1.7, 3.3, and 6.6
mg/liter polymyxin B base). Polymyxin B and colistin concentrations
were measured using a previously described and validated liquid chroma-
tography-tandem mass spectrometry assay (29).
Mechanism-based modeling. A mathematical model was developed
and fitted to the experimental data for each strain to correlate the time
course of polymyxin concentrations with bacterial killing and the emer-
gence of resistance (Fig. 2). The PK of polymyxin B or colistin in the IVM
was described by a one-compartment model with first-order elimination.
The mechanism-based PD model contained growth of multiple bacterial
populations, polymyxin target site binding, bacterial killing, and adaptive
polymyxin resistance (30, 31).
Bacterial growth model. For each A. baumannii strain, bacterial cells
were partitioned into 3 populations: polymyxin-susceptible (CFUS, equa-
tion 1), polymyxin-resistant (CFUR, equation 2), and dormant (i.e., non-
replicating or extremely slowly replicating; PopD, equation 3) bacteria.
Replication of polymyxin-susceptible and -resistant bacteria was modeled
as a first-order process, with separate growth rate constants for each pop-
ulation. The total bacterial population for each strain was constrained by
a logistic growth term that defined the maximum population size (32).
dCFUS
dt
 CFUS kgrowth,S 1 CFUtotalCFUmax  1 Fcost
 Killpolymyxin,eff kSD
CL
V  kDS PopD (1)
dCFUR
dt
 CFUR kgrowth,R  1 CFUtotalCFUmax  CLV  (2)
dPopD
dt
 kSD CFUS kDS CLV  PopD (3)
The parameters in these equations are explained in detail in Table 1
and Fig. 2. The resistant population was assumed to be totally resistant,
and therefore, equation 2 lacked a term for killing. Polymyxin-susceptible
bacteria were allowed to transition, in both directions, into and out of a
dormant state via a first-order process that rendered these cells both tol-
erant to polymyxin-induced killing and also nonobservable by viable
counting. The presence of viable but nonculturable bacterial cells has been
documented previously (33, 34); however, the impact of this phenome-
non on polymyxin activity and the emergence of resistance has not been
elucidated.
Polymyxin activity. A previously reported model was used to describe
the binding of polymyxin to its initial bactericidal target, the lipid A moi-
ety of LPS on the bacterial outer membrane (30). This model accounts for
the competitive displacement of bound divalent cations (Fbound,cations;
Ca2 and Mg2) from lipid A by polymyxins (equations 4 and 5). The
effective polymyxin concentration (Cpolymyxin,eff) was then calculated, ac-
counting for the occupancy of the lipid A binding site (Fpolymyxin,eff) and
the concentration of divalent cations in cation-adjusted Mueller-Hinton
broth (equation 6). Bacterial killing by polymyxin (Killpolymyxin,eff) was
described by a Hill equation (equation 7) that is commonly used to de-
scribe antimicrobial activity (35, 36).
FIG 2 Model structure of the developed mechanism-based model for polymyxin-mediated bacterial killing and the dynamics of constitutive and adaptive
polymyxin resistance. The washout of bacteria from the IVM has not been included in this diagram for clarity.
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Fbound,cations
Ccations
Kdcations Ccations
Kdcations
Kdpolymyxin

Cpolymyxin
MWpolymyxin
(4)
Fpolymyxin,eff
1 Fbound,cationsHillbinding
EC50
Hillbinding 1 Fbound,cationsHillbinding
(5)
Cpolymyxin,eff
Fpolymyxin,eff Cpolymyxin
1 Radaptive
(6)
Killpolymyxin,eff Killmax 
Cpolymyxin,eff
Hillkilling
KillC50
Hillkilling Cpolymyxin,eff
Hillkilling
(7)
Polymyxin resistance. Resistance to polymyxins was characterized as
either constitutive or adaptive. Constitutive polymyxin resistance was as-
sumed to be complete (i.e., no bacterial killing). Therefore, the killing rate
constant of the resistant population was zero. Adaptive resistance (also
called tolerance) affected the polymyxin-susceptible bacterial population
and reduced the effective polymyxin concentration (equation 6). In the
model, adaptive resistance (Radaptive) was described in a previously re-
ported (31) turnover model for adaptation (equations 8 and 9), account-
ing for effective polymyxin concentration (Stim). The term Smax repre-
sents the maximal fold reduction in the effective polymyxin concentration
due to adaptive resistance. This approach is closely aligned with previous
reports on the mechanism of adaptive polymyxin resistance, where lipid A
modifications (with nonanionic moieties such as arabinose/phosphoe-
thanolamine) lead to an attenuation of its electrostatic interaction with
polymyxins (37, 38). In two of the four A. baumannii strains (FADDI-
AB008 and FADDI-AB030), the experimental data supported the inclu-
sion of a fitness cost (Fcost) associated with adaptive polymyxin resistance
that slowed the replication rate of the susceptible population, depending
on the rate of adaptation (equation 10).
Stim Smax 
Cpolymyxin
SC50 Cpolymyxin
(8)
Radaptive kadapt Stim Radaptive (9)
Fcost Ginhib,max 
Radaptive
Smax
(10)
Observation model. The mathematical model outlined is premised
on the number of colonies observed in standard viable counting on drug-
free (CFUagar,drug-free) and drug-containing (CFUagar,drug-containing) plates
being representative of bacterial population dynamics. We had to develop
a new observation model, since current PK/PD models could not explain
the gradual emergence of antibiotic-resistant bacteria in the absence of
killing. This novel model was implemented to capture the contribution of
both constitutive and adaptive resistance to the number of colonies
formed on polymyxin-containing (6.6 mg/liter) agar plates. In this model,
the viable count on polymyxin-containing agar plates was equal to the
sum of the polymyxin-resistant population and the modeled proportion
of polymyxin-susceptible bacteria that remain viable following a 24-h
exposure to polymyxin at 6.6 mg/liter in agar (equation 12). The rate of
bacterial killing (equation 7) used to calculate the proportion of bacteria
that remained viable during incubation was assumed to be the killing rate
at the time of sampling, remaining unchanged during incubation.
CFUagar,drug-free CFUS CFUR (11)
CFUagar,drug-containing CFUS e
24Killpolymyxin,eff,t CFUR (12)
Parameter estimation, model qualification, and simulations. For
each A. baumannii strain, PK/PD model parameters were simultaneously
estimated in S-ADAPT (version 1.57) (39) using a Monte Carlo paramet-
ric expectation maximization algorithm (i.e., importance sampling
pmethod 4 in S-ADAPT). SADAPT-TRAN was used to facilitate mod-
eling analysis (40, 41). To assess the significance and overall contribution
of each model component, alternate simplified models that lacked the
respective model feature or parameter were fit to the experimental data.
The change in the objective function (2 log-likelihood) value was then
used to determine the importance of the model component that was sim-
plified.
The final model was then used to compare bacterial killing, bacterial
regrowth, and the emergence of resistance associated with previously re-
ported concentration-time profiles for colistin (8) and polymyxin B (9).
For colistin, the unbound concentration-time profile used in the simula-
tion mimicked that predicted by Plachouras et al. (8) following the ad-
TABLE 1 Population parameter estimates of the fitted models for each examined A. baumannii strain
Parameter (symbol and/or unit)
Mean (SE) for Acinetobacter baumannii strain:
ATCC 19606 AB307-0294 FADDI-AB008 FADDI-AB030
Initial inoculum for CFUtotal (log10 CFU/ml) 6.34 (3.14%) 6.14 (1.87%) 5.93 (4.14%) 6.17 (3.02%)
Initial inoculum for CFUR (log10 CFU/ml) 0.249 (95.2%) 0.503 (34.6%) 0.44 (73%) 0.0466 (6.13%)
Maximal bacterial population (CFUmax, log10 CFU/ml) 7.35 (1.04%) 8.05 (1.12%) 7.66 (1.07%) 7.82 (1.56%)
Mean turnover time CFUS (min) 75.2 (21.1%) 32 (10.7%) 35.2 (11.5%) 27.7 (10.2%)
Mean turnover time CFUR (min) 71.4 (12.3%) 81.0 (6.79%) 48.1 (9.58%) 313 (9.85%)
Transition rate constant to dormancy (kSD, h
1) 0.00635 (70%) 0.0367 (42.9%) 0.00246 (44.5%) 0.000916 (102%)
Transition rate constant out of dormancy (kDS, h
1) 3.19 (24.2%) 0.0332 (47.1%) 5.45 (38.9%) 7.05 (15.7%)
Hill coefficient for polymyxin binding to LPS (Hillbinding) 3.06 (16.2%) 4.13 (30.3%) 3.25 (68.2%) 4.83 (18.3%)
EC50
b for polymyxin binding to LPS (EC50) 0.0483 (8.25%) 0.0989 (9.76%) 0.0237 (19.7%) 0.0173 (7.17%)
Maximal polymyxin-induced killing rate constant (Killmax, h
1) 100 (fixed) 100 (fixed) 100 (fixed) 100 (fixed)
Hill coefficient for polymyxin-induced killing (Hillkilling) 3.85 (20%) 2.79 (9.64%) 1.75 (13%) 19.5 (14.9%)
EC50 for polymyxin-induced killing (KillC50, mg/liter) 0.521 (22.5%) 0.561 (22.3%) 0.693 (23.9%) 0.516 (13.1%)
Maximal fold reduction in the effective polymyxin concn due to
adaptive resistance (Smax)
300 (fixed) 300 (fixed) 300 (fixed) 300 (fixed)
Adaptation rate constant (kadapt, h
1) 7.20 (16.5%) 14.2 (12.9%) 8.09 (16.3%) 15.2 (10.5%)
Maximal fitness cost associated with resistance (Ginhib,max) NE
a NE 0.994 (9.43%) 0.991 (5.07%)
In vitro model flow rate (CL, liters/h) 0.00434 (10.4%) 0.00506 (9.14%) 0.00585 (9.97%) 0.00476 (8.98%)
In vitro model reservoir vol (V, liters) 0.111 (13.5%) 0.101 (13.6%) 0.119 (9.87%) 0.133 (17.6%)
a NE, not estimated: parameters were not included for estimation in the model, as the experimental data did not support the inclusion of this feature for these strains.
b EC50, 50% effective concentration.
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ministration of a 12-MU CMS loading dose (360 mg CBA) followed by
4.5 MU (140 mg CBA) every 12 hours in a patient with normal creati-
nine clearance. In the case of polymyxin B, the unbound concentration-
time profile representative of the 50th percentile of Monte Carlo simula-
tions reported by Sandri et al. (9) following a loading dose of 2 mg/kg of
body weight (2-h infusion) and a daily maintenance dose of 1.25 mg/kg
(1-h infusion) was used. The unbound concentrations for both polymyx-
ins were calculated based upon 50% plasma protein binding (9, 26, 27).
Model simulations were performed in Berkeley Madonna using the pop-
ulation mean parameter estimates based on the experimental data for
polymyxin-heteroresistant A. baumannii strain AB307-0294.
RESULTS
The gradual accumulation of colistin arising from regimen R1
(Fig. 1A) resulted in little antibacterial activity against all the ex-
amined A. baumannii strains (Fig. 3B, 4B, 5B, and 6B). Indeed,
overall the time course of CFU per milliliter for each strain was
similar to that for the corresponding growth control (panels A in
each of Fig. 3 to 6). The maximum observed bacterial killing of1
log10 CFU/ml was achieved between 47 and 49 h after commenc-
ing treatment (Fig. 6), despite achieving colistin base concentra-
tions greater than 1 mg/liter (equivalent to 1.26 mg/liter colistin
sulfate) within 24 h. Further, amplification of polymyxin-resistant
bacterial populations was observed in the PAPS after approxi-
mately 48 h of colistin exposure in all examined strains. At the
conclusion of treatment, a significant proportion of the bacterial
population was polymyxin resistant. Analysis of the PAPs revealed
a modest difference (3 log10 CFU/ml) between viable counts on
drug-free and 6.6-mg/liter polymyxin B plates for allA. baumannii
strains except ATCC 19606, where the difference was 4 log10
CFU/ml.
FIG 3 Observed data (points) and individual model fits (lines) for total viable bacteria ( and thick solid line), resistant bacteria (Œ and thick dashed line), and
polymyxin concentrations (}, dotted line) for control (A), gradual rise of colistin (R1) (B), polymyxin B with no loading dose (R2) (C), a conventional loading
dose (R3) (D), and augmented loading dose (R4) (E) against A. baumannii strain ATCC 19606.
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In contrast, all three polymyxin B dosage regimens (Fig. 1)
displayed good initial antibacterial activity against the examined
A. baumannii strains, achieving4 log10 CFU/ml killing within 1
h of treatment initiation (panels C to E in each of Fig. 3 to 6).
However, bacterial regrowth was observed at 11 to 13 h after the
initiation of therapy. By 96 h, bacterial density was 7 log10
CFU/ml for all dosage regimens and strains examined. The bacte-
rial population following regrowth was polymyxin resistant, with
a 1-log10 CFU/ml difference in viable counts at 96 h between
drug-free and polymyxin B-containing (6.6 mg/liter) plates for all
strains except AB307-0294 (Fig. 4). Against A. baumannii strains
FADDI-AB008 and FADDI-AB030, administration of the regi-
men with an augmented loading dose of polymyxin B (R4, Fig. 5E
and 6E) resulted in delayed and slow bacterial regrowth compared
to that observed with R2 (Fig. 5C and 6C). The administration of
loading doses did not materially affect the regrowth ofA. bauman-
nii strains ATCC 19606 and AB307-0294 (panels E versus C in Fig.
3 and 4).
The developed mechanism-based PK/PD model (Fig. 2) de-
scribed well the kinetics of bacterial killing and regrowth of A.
baumannii on antibiotic-free and antibiotic-containing agar
plates (Table 1; Fig. 3 to 6). To improve numerical stability during
the estimation, the maximal bacterial killing rate (Killmax) was
fixed to 100 h1 (equivalent to 11 log10 killing in 15 min) and the
maximal attenuation in killing (i.e., extent of adaptive resistance;
Smax) to 300. Model qualification demonstrated the significant
contribution (P 0.05) of each component to model fits, with the
objective function (2 log likelihood) worsening with the omis-
sion of any individual component for at least 2 of 4 strains
(Table 2).
FIG 4 Observed data (points) and individual model fits (lines) for total viable bacteria ( and thick solid line), resistant bacteria (Œ and thick dashed line), and
polymyxin concentrations (}, dotted line) for control (A), gradual rise of colistin (R1) (B), polymyxin B with no loading dose (R2) (C), a conventional loading
dose (R3) (D), and augmented loading dose (R4) (E) against A. baumannii strain AB307-0294.
Cheah et al.
3926 aac.asm.org July 2016 Volume 60 Number 7Antimicrobial Agents and Chemotherapy
Examination of the modeled bacterial population dynamics
revealed that adaptive resistance was a primary mode of poly-
myxin resistance enabling bacterial regrowth during polymyxin
treatment. The mechanism-based model also strongly implicated
the involvement of viable but nonculturable bacterial cells in bac-
terial regrowth during polymyxin treatment; deletion of this
model feature resulted in a substantial worsening in the objective
function (Table 2).
Simulations conducted using the model fitted for A. bauman-
nii AB307-0294 suggested that unbound colistin concentration-
time profiles achieved with the use of aggressive CMS loading
doses (Fig. 7A) would result in3 log10 CFU/ml killing (Fig. 7B).
In contrast, the simulated polymyxin B dosage regimen (Fig. 7C)
resulted in more-rapid and 2-log10 CFU/ml-greater bacterial
killing than that obtained with the CMS dosage regimen (Fig. 7D).
Regrowth of polymyxin-resistant bacteria due to adaptive resis-
tance, as well as the amplification of constitutively polymyxin-
resistant subpopulations (0.001% of total bacteria;1,000-fold
amplification), was predicted within less than 24 h with both dos-
age regimens.
DISCUSSION
The resurgence in clinical usage of polymyxins and their impor-
tance as “last-line” therapeutic agents for the treatment of infec-
tions caused by MDR Gram-negative organisms necessitates in-
vestigations into the factors that influence polymyxin activity and
the development of resistance. Colistin and polymyxin B, the two
clinically used polymyxins, share similar in vitro activity but differ
substantially in the time course of concentrations achieved in the
hours, and potentially days, following initiation of therapy due to
FIG 5 Observed data (points) and individual model fits (lines) for total viable bacteria ( and thick solid line), resistant bacteria (Œ and thick dashed line), and
polymyxin concentrations (}, dotted line) for control (A), gradual rise of colistin (R1) (B), polymyxin B with no loading dose (R2) (C), a conventional loading
dose (R3) (D), and augmented loading dose (R4) (E) against A. baumannii strain FADDI-AB008.
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their administered forms (7). In this report, we have employed a
dynamic in vitro PK/PD model and mathematical modeling to
explore the effects of differences in concentration-time profiles on
the activity of polymyxins and the development of polymyxin re-
sistance due to amplification of preexisting resistant mutants and
adaptive resistance (42, 43). The developed mathematical model
implemented a new observation model that linked adaptive resis-
tance to colony formation on drug-containing plates, extending
the utility of previous models of adaptive resistance (31, 44).
The one-compartment IVM was able to simulate clinically rel-
evant polymyxin B and colistin concentration-time profiles, as
seen in previously published studies (5, 8, 9). It should be noted
that the polymyxin concentrations investigated in the IVM were
in the region of the upper limits of unbound polymyxin concen-
trations seen in critically ill patients, to account for the previously
observed resilience of A. baumannii to treatment with colistin
(45). For colistin, an unbound Css,avg of 3 mg/liter would be pos-
sible only in a patient with moderate renal function receiving
300 to 360 mg CBA each day; patients with higher renal function
achieve substantially lower concentrations (5). Of great concern
was our finding that the gradual rise in colistin concentrations to a
Css,avg of 3 mg/liter enabled the acquisition of polymyxin resis-
tance to outpace the accumulation of colistin, leading to little
bacterial killing over the treatment period. In contrast, all the
polymyxin B dosage regimens showed good bacterial killing dur-
ing the initial stages of treatment, likely as a result of achieving
bactericidal concentrations prior to the onset of adaptive poly-
myxin resistance. Notably, the emergence of polymyxin-resistant
bacterial populations was substantial following treatment with ei-
ther colistin or polymyxin B dosage regimens, despite significant
FIG 6 Observed data (points) and individual model fits (lines) for total viable bacteria ( and thick solid line), resistant bacteria (Œ and thick dashed line), and
polymyxin concentrations (}, thick dotted line) for control (A), gradual rise of colistin (R1) (B), polymyxin B with no loading dose (R2) (C), a conventional
loading dose (R3) (D), and augmented loading dose (R4) (E) against A. baumannii strain FADDI-AB030.
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differences in the magnitude of bacterial killing. Taken together,
these findings show the clear link between the rapid attainment of
therapeutic polymyxin concentrations and bacterial killing and
the alarming rate at which resistance to polymyxin develops.
In this study, polymyxin B loading doses (conventional and
augmented) were found to slow the rate of bacterial regrowth for
FADDI-AB030 (conventional and augmented loading doses) and
FADDI-AB008 (augmented loading dose only). A similarly clear
TABLE 2 Model validation results, showing the change in2 log likelihood associated with modifying and deleting model features
Model features
Resulta for Acinetobacter baumannii strain:
ATCC 19606 AB307-0294 FADDI-AB008 FADDI-AB030
Simplified model
Contribution of susceptible bacteria to viable counts on
drug-containing plates, equation 12
NSa 77.6 NS 96.5
Transition of susceptible bacteria into a dormant,
nonculturable, polymyxin-resistant state, equation 3
30.6 65.9 11.6 109.8
Constitutively highly polymyxin-resistant bacteria,
equation 2
488.5 391.7 338.0 281.3
Adaptive resistance, equations 8 and 9 82.3 —b — —
Alternative model specification
Linear relationship between polymyxin concn and
bacterial killing
73.9 136.6 — 128.9
Three transit compartments for adaptive resistance
(instead of one; equation 9)
NS 38.1 NS 51.3
Five transitory compartments for adaptive resistance
(instead of one; equation 9)
NS 74.6 24.4 50.8
a NS, not significant: the data did not support inclusion of this feature in the model for the respective strain.
b —, feature lacking: the models that lacked this feature could not be robustly estimated for the respective strain(s), most likely since the simplified model provided very poor curve
fits. This strongly suggested that the respective model feature was beneficial and should be included.
FIG 7 Model simulation results for A. baumannii strain AB307-0294 (initial inoculum, 106 CFU/ml) treated with unbound concentration-time profiles adapted
from population PK studies (8, 9) of colistin following CMS administration in a patient with normal renal function (360 mg colistin base activity loading dose,
140 mg every 12 h maintenance dose) (A) and a polymyxin B dosage regimen representing the 50th percentile of critically ill patients receiving a 2-mg/kg
polymyxin B loading dose, followed by 1.25 mg/kg every 12 h (C). The dynamics of initially susceptible (adaptive resistance) (solid line) and constitutively
resistant (dashed line) bacterial populations are shown separately (B and D).
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relationship between the use of loading doses and improved sup-
pression of bacterial regrowth was not seen in the remaining A.
baumannii strains, ATCC 19606 and AB307-0294. The mechanis-
tic basis of this observed slowing in the bacterial regrowth rate in
A. baumannii when treated with polymyxin B loading doses re-
mains to be elucidated; however, it has been suggested that het-
eroresistance plays a significant role in determining the rate at
which antimicrobial resistance emerges (21).
Despite the growing body of clinical evidence surrounding the
beneficial effect of rapid attainment of therapeutic antibiotic con-
centrations (15–17) and the demonstration of superior activity of
polymyxin B loading doses in vitro against some strains in the
current study, the benefits of polymyxin B loading doses have not
been thoroughly investigated clinically. Clearly, the implications
of such dosage regimens on nephrotoxicity should be carefully
considered. The key drivers of polymyxin-induced nephrotoxicity
are the subject of continuing research (46–49), and findings from
those studies will be integral to the development of clinical guide-
lines for safe and effective polymyxin B dosing.
Current literature suggests that polymyxin resistance in A.
baumannii is driven by either the modification of the lipid A moi-
ety of LPS or the loss of LPS from the outer membrane (22, 23, 37,
50). In other bacterial species, these changes to the bacterial outer
membrane arise due to preexisting mutations or adaptive re-
sponses to polymyxins (38). The dynamics between constitutively
polymyxin-resistant (mutants) and adaptively polymyxin-resis-
tant bacterial populations during polymyxin therapy have not
been previously investigated. In line with recently published rec-
ommendations (51), the new mechanism-based model described
in this report built upon prior work (35, 36, 52) on modeling
antimicrobial activity and incorporated both of these resistance
mechanisms, in addition to reversible dormancy. The model was
able to describe well the observed viable counts on both antibiotic-
free and antibiotic-containing agar plates (Fig. 3 to 6).
Analysis of the bacterial population dynamics as described by
the mechanism-based model pointed to adaptive resistance as a
key factor driving bacterial regrowth following treatment with
clinically relevant dosage regimens in the IVM. Further, dormant,
nonculturable bacterial cells were identified as a likely contributor
to bacterial regrowth following polymyxin treatment. Exclusion
of dormant cells from the model resulted in implausible parame-
ter estimates for bacterial replication times (15 min) to describe
the bacterial regrowth following polymyxin-induced bacterial
killing. Dormant and slow-growing bacterial cells have been re-
ported to be involved in penicillin resistance in Escherichia coli
(53). Further investigations that enable direct observation of bac-
terial cells (e.g., single-cell microfluidic microscopy) will be re-
quired to examine this phenomenon inA. baumanniiduring poly-
myxin treatment.
The use of a CMS loading dose to hasten the attainment of
therapeutic colistin concentrations has been previously proposed
(8, 11, 27, 54, 55). It should be noted that the reported disposition
of formed colistin following CMS administration shows substan-
tial variance; a recent report on the disposition of CMS/colistin in
critically ill patients has described the rapid formation of colistin
following CMS administration (55). However, these findings are
contrary to previous reports from multiple investigators across
several continents (5, 8, 27, 56). The reasons for the divergence in
results remain to be elucidated, and interbrand variability has
been hypothesized to be a key contributor (55). A concentration-
time profile representative of the more commonly reported phar-
macokinetics of CMS/colistin in patients with normal renal func-
tion was examined using the mechanism-based model fitted on
data from A. baumannii AB307-0294 (Fig. 7). Compared to a
polymyxin B dosage regimen with a loading dose as proposed by
Sandri et al. (9), the CMS regimen was slow to achieve polymyxin
concentrations of 1 mg/liter (cf. 4 h for CMS and 1 h for
polymyxin B).
Mathematical model simulations indicated that the CMS reg-
imen was likely to result in 2 log10 CFU/ml less bacterial killing
(i.e., 3 log10 versus 5 log10) compared to the polymyxin B
dosage regimen (Fig. 7). Model simulations for colistin and poly-
myxin B also predicted the amplification of constitutively poly-
myxin-resistant bacteria, in line with the previously identified link
between the isolation of heteroresistant A. baumannii and prior
treatment with colistin in critically ill patients (57). Heteroresis-
tance in A. baumannii has been documented previously (19, 20,
45), and the clinical impact of these highly polymyxin-resistant
bacteria remains to be fully established. However, it seems highly
possible that these resistant mutants contribute to clinical failure
(21). Conclusive evidence of these phenomena will require molec-
ular confirmation of the modalities of polymyxin resistance
mechanisms. Although optimization of polymyxin monotherapy
remains as an important goal, a worrying trend in the experimen-
tal and simulation data was the regrowth of polymyxin-resistant
bacteria across all strains and dosage regimens, a finding common
to numerous previously published investigations into polymyxin
activity against Gram-negative pathogens in vitro (45, 58, 59).
These results suggest that simply optimizing polymyxin mono-
therapy is unlikely to be adequate to prevent the emergence of
resistance and that polymyxin combination therapies must be
explored as a strategy to combat multidrug resistance in A.
baumannii.
A potential limitation of this study, and a key consideration, is
the lack of a functioning immune system in the applied dynamic in
vitro experimental model. Studies into granulocyte-mediated bac-
terial killing ofPseudomonas aeruginosa suggest that a reduction in
bacterial burden to 6 log10 CFU/ml is likely to prevent satura-
tion of bacterial killing by granulocytes and improve clinical out-
comes (60, 61). The in vitro and in silico data from the present
study point to bacterial killing of3 log10 CFU/ml for polymyxin
B dosage regimens with loading doses, suggesting that adequate
polymyxin dosage regimens will reduce the bacterial burden suf-
ficiently to prevent saturation of granulocyte-mediated killing.
Translation of these findings into treatment options for critically
ill patients with partially suppressed immune systems will require
further investigation and consideration of other clinical factors.
In conclusion, this study demonstrated that clinically relevant
concentration-versus-time profiles of colistin resulted in slower
and less-extensive bacterial killing than that seen with polymyxin
B dosage regimens that rapidly attained target concentrations.
These findings demonstrate the advantages of polymyxin B over
colistin (administered as CMS) with regard to rapid target con-
centration attainment and antibacterial activity. Mechanism-
based modeling of bacterial populations also showed the impor-
tant influence of the time course of polymyxin concentration over
the first several hours of therapy on the population dynamics be-
tween adaptive and constitutively resistant bacterial cells. This in-
formation will be critical in the optimization of polymyxin ther-
Cheah et al.
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apy against A. baumannii as well as the rational design of
synergistic combination therapies containing polymyxins.
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